Patents by Inventor Laurent Jespers
Laurent Jespers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10466252Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: February 10, 2014Date of Patent: November 5, 2019Assignee: Glaxo Group LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
-
Patent number: 10302655Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: August 17, 2017Date of Patent: May 28, 2019Assignee: Glaxo Group LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
-
Publication number: 20190040148Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: July 27, 2018Publication date: February 7, 2019Inventors: Laurent JESPERS, Malgorzata Pupecka-Swider, Carolyn Enever, Ian Tomlinson
-
Patent number: 10072089Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: December 21, 2016Date of Patent: September 11, 2018Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka-Swider, Carolyn Enever, Ian Tomlinson
-
Publication number: 20180088128Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: August 17, 2017Publication date: March 29, 2018Inventors: Carolyn ENEVER, Laurent JESPERS, Malgorzata PUPECKA-SWIDER, Ian TOMLINSON
-
Publication number: 20170174775Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventors: Laurent JESPERS, Malgorzata PUPECKA-SWIDER, Carolyn Enever, Ian Tomlinson
-
Publication number: 20170145080Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.Type: ApplicationFiled: October 28, 2015Publication date: May 25, 2017Inventors: Ian TOMLINSON, Laurent Jespers, Jasper Clube, Lucy J. Holt., Oliver Schon
-
Patent number: 9562090Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: February 11, 2013Date of Patent: February 7, 2017Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Carolyn Enever, Ian Tomlinson
-
Publication number: 20160207993Abstract: The invention relates to antigen-binding constructs comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding construct has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.Type: ApplicationFiled: June 15, 2015Publication date: July 21, 2016Inventors: Claire ASHMAN, Thil Batuwangala, Michael Neil Burden, Stephanie Jane Clegg, Rudolf Maria De Wildt, Jonathan Henry Ellis, Paul Andrew Hamblin, Farhana Hussain, Laurent Jespers, Alan Lewis, Martin Anibal Orecchia, Radha Shah, Michael Steward
-
Patent number: 9321832Abstract: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity.Type: GrantFiled: February 8, 2007Date of Patent: April 26, 2016Assignee: Domantis LimitedInventors: Ian Tomlinson, Laurent Jespers, Jasper Clube, Lucy J. Holt, Oliver Schon
-
Patent number: 8877186Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: GrantFiled: June 3, 2008Date of Patent: November 4, 2014Assignee: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Publication number: 20140187750Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Glaxo Group LimitedInventors: Carolyn ENEVER, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson
-
Patent number: 8685895Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: December 4, 2009Date of Patent: April 1, 2014Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian M Tomlinson
-
Patent number: 8398979Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 4, 2008Date of Patent: March 19, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Patent number: 8357780Abstract: The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 3, 2008Date of Patent: January 22, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20120134982Abstract: The present invention relates to polypeptides e.g. protease resistant polypeptides, immunoglobulin (antibody) single variable domains e.g. which are protease resistant and also to vascular endothelial growth factor (VEGF) antagonists comprising these. The invention further relates to uses, formulations, and compositions comprising such polypeptides e.g. for delivery to the eye.Type: ApplicationFiled: November 17, 2011Publication date: May 31, 2012Inventors: Fiona COOK, Gerald Gough, Michael Steward, Laurent Jespers
-
Publication number: 20120064064Abstract: The present invention relates to antigen binding proteins comprising an immunoglobulin heavy chain and an immunoglobulin light chain, wherein the heavy chain comprises an epitope binding domain linked to the n-terminus of CH1-CH2-CH3, and the light chain comprises an epitope binding domain linked to the n-terminus of CL, wherein one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin heavy chain, and/or one or more epitope-binding domains are linked to the C-terminus of the immunoglobulin light chain, methods for making such proteins, and uses thereof.Type: ApplicationFiled: May 26, 2010Publication date: March 15, 2012Inventors: Thil Dinuk Batuwangala, Laurent Jespers, Michael Steward
-
Publication number: 20110256122Abstract: The present disclosure relates to immunoglobulin single variable domains (dAbs) e.g., dAbs which are protease resistant, and also to formulations, and compositions comprising such dAbs for ocular delivery and to their uses to treat ocular diseases and conditions.Type: ApplicationFiled: November 4, 2009Publication date: October 20, 2011Inventors: Ian Richard Catchpole, Fiona Cook, Gerald Gough, Laurent Jespers, Michael Steward
-
Publication number: 20110229458Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: December 4, 2009Publication date: September 22, 2011Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian M. Tomlinson
-
Publication number: 20110086019Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: June 3, 2008Publication date: April 14, 2011Applicant: Domantis LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Armin Sepp